BMRN · Biomarin Pharmaceutical Inc · Earnings Call Transcripts & Audio
$60.00
+0.13 (+0.22%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$11.59B
Shares
193.57M
Volume · Sep 30
1.8M
Avg daily vol (3M)
1.94M
Biomarin Pharmaceutical Inc Earnings Call Transcripts
Quarterly earnings calls for Biomarin Pharmaceutical Inc (BMRN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.6%
$505.34M
−$6.65M
'22 Q3
22-10-26
▲19.5%
$537.54M
−$249,000
'22 Q4
23-02-27
▲14.8%
$596.41M
$50.85M
'23 Q1
23-04-26
▲11.5%
$595.27M
$56.04M
'23 Q2
23-07-31
▲15%
$581.33M
$40.38M
'23 Q3
23-11-01
▲20.2%
$646.21M
$20.38M
'23 Q4
24-02-22
▲8.8%
$648.83M
$88.66M
'24 Q1
24-04-24
▲19.6%
$712.03M
$107.17M
'24 Q2
24-08-05
▲28.3%
$745.74M
$106.08M
'24 Q3
24-10-29
▲15.6%
$747.31M
$124.94M
'24 Q4
25-02-19
▲14.8%
$745.14M
$185.69M
'25 Q1
25-05-16
▲15.9%
$825.41M
$240.53M
'25 Q2
25-08-04
▲4.1%
$776.13M
−$30.74M
'25 Q3
25-10-27
▲17%
$874.57M
−$46.57M
'25 Q4
26-02-23
▲2.8%
$766.21M
$105.53M
'26 Q1
26-05-04
LATEST
▲19.9%
$989.71M
$44.76M
'26 Q2
26-08-06
Conference
Investor event
2026-09-09
Biomarin Pharmaceutical Inc (BMRN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Biomarin Pharmaceutical Inc (BMRN) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Biomarin Pharmaceutical Inc (BMRN) Q2 2026 Earnings Call Transcript
Confident tone
Voxzogo (Vosoritide) Performance and Expansion
Galafold (Fabry Disease) Commercial Outlook
Amicus Acquisition Integration
Revenue
$989.71M
▲ 19.9% YoY Diluted EPS
$0.23
▼ 81.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
Biomarin Pharmaceutical Inc (BMRN) Q1 2026 Earnings Call Transcript
Confident tone
Voxzogo commercial momentum
Amicus acquisition and integration
Enzyme Therapies growth
Revenue
$766.21M
▲ 2.8% YoY Diluted EPS
$0.54
▼ 43.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Biomarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Transcript
Confident tone
Revenue growth and franchise performance
Voxzogo label expansion (hypochondroplasia)
Inorganic growth via acquisitions
Revenue
$874.57M*
▲ 17% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-27
Biomarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Transcript
Positive tone
VOXZOGO growth and achondroplasia franchise
Hypochondroplasia label expansion
Enzyme Therapies business unit
Revenue
$776.13M
▲ 4.1% YoY Diluted EPS
$-0.16
▼ 129.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biomarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Transcript
Confident tone
Revenue growth and full-year guidance raise
BMN 333 (long-acting achondroplasia therapy) Phase II/III
BMN 401 / Inozyme acquisition and ENERGY III trial
Revenue
$825.41M
▲ 15.9% YoY Diluted EPS
$1.23
▲ 123.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-16
Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Transcript
Confident tone
VOXZOGO franchise
Pipeline and R&D
Revenue and earnings growth
Revenue
$745.14M
▲ 14.8% YoY Diluted EPS
$0.95
▲ 106.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Biomarin Pharmaceutical Inc (BMRN) Q4 2024 Earnings Call Transcript
Confident tone
VOXZOGO growth and franchise leadership
Pipeline catalysts and clinical data
Enzyme therapy franchise durability
Revenue
$747.31M*
▲ 15.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Transcript
Confident tone
VOXZOGO growth and Skeletal Conditions franchise
BMN 333 long-acting CNP development
Enzyme Therapies portfolio performance
Revenue
$745.74M
▲ 28.3% YoY Diluted EPS
$0.55
▲ 161.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biomarin Pharmaceutical Inc (BMRN) Q2 2024 Earnings Call Transcript
Confident tone
VOXZOGO commercial momentum and label expansion
ROCTAVIAN strategic reset and focused launch
Revenue timing dynamics between orders and patients
Revenue
$712.03M
▲ 19.6% YoY Diluted EPS
$0.55
▲ 89.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript
Positive tone
Voxzogo growth and label expansion
Roctavian commercial challenges
Investor Day strategy reveal
Revenue
$648.83M
▲ 8.8% YoY Diluted EPS
$0.46
▲ 70.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Biomarin Pharmaceutical Inc (BMRN) Q4 2023 Earnings Call Transcript
Confident tone
VOXZOGO commercial acceleration
Financial performance and 2024 guidance
ROCTAVIAN launch and uptake
Revenue
$646.21M*
▲ 20.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Biomarin Pharmaceutical Inc (BMRN) Q3 2023 Earnings Call Transcript
Revenue
$581.33M
▲ 15% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-31
Biomarin Pharmaceutical Inc (BMRN) Q2 2023 Earnings Call Transcript
Revenue
$595.27M
▲ 11.5% YoY Diluted EPS
$0.29
▲ 93.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Biomarin Pharmaceutical Inc (BMRN) Q1 2023 Earnings Call Transcript
Revenue
$596.41M
▲ 14.8% YoY Diluted EPS
$0.27
▼ 57.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Biomarin Pharmaceutical Inc (BMRN) Q4 2022 Earnings Call Transcript
Revenue
$537.54M*
▲ 19.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Biomarin Pharmaceutical Inc (BMRN) Q3 2022 Earnings Call Transcript
Revenue
$505.34M
▲ 23.6% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-25
Biomarin Pharmaceutical Inc (BMRN) Q2 2022 Earnings Call Transcript
Revenue
$533.80M
▲ 6.4% YoY Diluted EPS
$0.15
▲ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Biomarin Pharmaceutical Inc (BMRN) Q1 2022 Earnings Call Transcript
Revenue
$519.36M
▲ 6.9% YoY Diluted EPS
$0.63
▲ 600% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Biomarin Pharmaceutical Inc (BMRN) Q4 2021 Earnings Call Transcript
Revenue
$449.81M*
▼ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Biomarin Pharmaceutical Inc (BMRN) Q3 2021 Earnings Call Transcript
Revenue
$408.74M
▼ 14.3% YoY Diluted EPS
$-0.20
▼ 105% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Biomarin Pharmaceutical Inc (BMRN) Q2 2021 Earnings Call Transcript
Revenue
$501.69M
▲ 16.8% YoY Diluted EPS
$0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript
Revenue
$486.03M
▼ 3.2% YoY Diluted EPS
$0.09
▼ 79.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
Revenue
$452.12M*
▼ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript
Revenue
$476.78M
▲ 3.4% YoY Diluted EPS
$4.01
▲ 1236.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Biomarin Pharmaceutical Inc (BMRN) Q2 2020 Earnings Call Transcript
Revenue
$429.49M
▲ 10.8% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Biomarin Pharmaceutical Inc (BMRN) Q1 2020 Earnings Call Transcript
Revenue
$502.07M
▲ 25.3% YoY Diluted EPS
$0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Biomarin Pharmaceutical Inc (BMRN) Q4 2019 Earnings Call
Revenue
$454.44M*
▲ 28.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
14 filings
11 filers
Visit website
Investor relations